In 5-year follow-up of the phase III CheckMate 648 trial in untreated advanced oesophageal squamous-cell carcinoma with PD-L1 ≥1%, nivolumab plus chemotherapy or ipilimumab improved overall survival vs chemotherapy (both HR 0.62). Grade 3–4 toxicity: 49%, 33% and 37%.
RCTn = 970
Kato et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648